HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

MRZ-8456

negative allosteric modulator of mGluR5 developed by Merz Pharmaceuticals

Also Known As:

6-bromo-pyrazolo(l,5-a)pyrimidin-2-yl)-(l(R)-methyl-3,4-dihydro-lH-isoquinolin-2-yl)-methanone

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - MRZ-8456: 1
  - Pyrimidines: 510
    - MRZ-8456: 1
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Isoquinolines: 34
      - MRZ-8456: 1

Experts

1.	Danysz, Wojciech: 1 article (11/2018)
2.	Dekundy, Andrzej: 1 article (11/2018)
3.	Gravius, Andreas: 1 article (11/2018)
4.	Westmark, Cara J: 1 article (11/2018)
5.	Westmark, Pamela R: 1 article (11/2018)

Related Diseases

1.	Seizures (Absence Seizure) 11/01/2018 - "Both MRZ-8456 and AFQ-056 attenuated wild running and audiogenic-induced seizures in Fmr1KO mice with similar pharmacokinetic profiles. " 11/01/2018 - "These findings demonstrate that MRZ-8456, a drug being developed for the treatment of motor complications of L-DOPA in Parkinson's disease and which completed a phase I clinical trial, is effective in attenuating both well-established (seizures and dendritic spine maturity) and exploratory biomarker (APP expression) phenotypes in a mouse model of fragile X syndrome."
2.	Parkinson Disease (Parkinson's Disease) 11/01/2018 - "These findings demonstrate that MRZ-8456, a drug being developed for the treatment of motor complications of L-DOPA in Parkinson's disease and which completed a phase I clinical trial, is effective in attenuating both well-established (seizures and dendritic spine maturity) and exploratory biomarker (APP expression) phenotypes in a mouse model of fragile X syndrome."
3.	Fragile X Syndrome (Martin Bell Syndrome) 11/01/2018 - "These findings demonstrate that MRZ-8456, a drug being developed for the treatment of motor complications of L-DOPA in Parkinson's disease and which completed a phase I clinical trial, is effective in attenuating both well-established (seizures and dendritic spine maturity) and exploratory biomarker (APP expression) phenotypes in a mouse model of fragile X syndrome."

Related Drugs and Biologics

1.	Biomarkers (Surrogate Marker)
2.	Levodopa (L Dopa)